Blocking of integrin-mediated human MV3 melanoma cell binding by commercial and modified heparins

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 7, 2010, Pages 448-450

  Schlesinger, M ^a   Naggi, A ^b   Torri, G ^b   Zeisig, R ^c   Alexander, M ^a   Schmitz, P ^a   Casu, B ^b   Bendas, G ^a  

^a UNIVERSITY OF BONN   (Germany)

^b Istituto di Ricerche Chimiche e Biochimiche G Ronzoni   (Italy)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Antimetastatic activity; Cell adhesion; Heparin; Melanoma; VLA 4

Indexed keywords

HEPARIN; HEPARIN DERIVATIVE; INTEGRIN; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ACETYLATION; CANCER CELL CULTURE; CELL ADHESION; CELL INTERACTION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; INHIBITION KINETICS; MELANOMA; MELANOMA CELL; METASTASIS INHIBITION; MICROSCOPY; PROTEIN BINDING; SHEAR RATE;

EID: 77954941422     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48448     Document Type: Conference Paper

References (7)

1. Casu B, Vlodavsky I, Sanderson RD. Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb. 2008; 36: 195-203.
2. Fritzsche J, Simonis D, Bendas G. Melanoma cell adhesion can be blocked by heparin in vitro: suggestion of VLA-4 as a novel target for antimetastatic approaches. Thromb Haemost. 2008; 100: 1166-1175.
3. Hostettler N, Naggi A, Torri G, Ishai-Michaeli R, Casu B, Vlodavsky I, Borsig L. P-selectin and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J. 2007; 21: 3562-3572. (Pubitemid 350075146)
4. Kakkar, A Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RC. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced outcome study (FAMOUS). J Clin Oncol. 2004; 22: 1944-1948. (Pubitemid 41095187)
5. Naggi A. Glycol-splitting as a device for modulating inhibition of growth factors and heparanase by heparin and heparin derivatives. In: Garg HG, Linhardt RJ, Hales CA (eds). Chemistry and biology of heparin and heparan sulfate. Amsterdam: Elsevier; 2005. p. 461-476.
6. Naggi A, Casu B, Perez M, Torri G, Cassinelli G, Penco S, Pisano C, Giannini G, Ishai-Michaeli R, Vlodavsky I. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol-splitting. J Biol Chem. 2005; 280: 12103-12113. (Pubitemid 40491020)
7. Schlesinger M, Simonis D, Schmitz P, Fritzsche J, Bendas G. Binding between heparin and the integrin VLA-4. Thromb Haemost. 2009; 102: 816-822.